Comparison of the Utility of Preoperative Versus Postoperative B-type Natriuretic Peptide for Predicting Hospital Length of Stay and Mortality After Primary Coronary Artery Bypass Grafting

Overview

Journal Anesthesiology

Specialty Anesthesiology

Date 2010 Mar 11

PMID 20216395

Citations 13

Authors

Amanda A Fox

Jochen D Muehlschlegel

Simon C Body

Stanton K Shernan

Kuang-Yu Liu

Tjorvi E Perry

Sary F Aranki

E Francis Cook

Edward R Marcantonio

Charles D Collard

Affiliations

Soon will be listed here.

Abstract

Background: Preoperative B-type natriuretic peptide (BNP) is known to predict adverse outcomes after cardiac surgery. The value of postoperative BNP for predicting adverse outcomes is less well delineated. The authors hypothesized that peak postoperative plasma BNP (measured postoperative days 1-5) predicts hospital length of stay (HLOS) and mortality in patients undergoing primary coronary artery bypass grafting, even after adjusting for preoperative BNP and perioperative clinical risk factors.

Methods: This study is a prospective longitudinal study of 1,183 patients undergoing primary coronary artery bypass grafting surgery. Mortality was defined as all-cause death within 5 yr after surgery. Cox proportional hazards analyses were conducted to separately evaluate the associations between peak postoperative BNP and HLOS and mortality. Multivariable adjustments were made for patient demographics, preoperative BNP concentration, and clinical risk factors. BNP measurements were log10 transformed before analysis.

Results: One hundred fifteen deaths (9.7%) occurred in the cohort (mean follow-up = 4.3 yr, range = 2.38-5.0 yr). After multivariable adjustment for preoperative BNP and clinical covariates, peak postoperative BNP predicted HLOS (hazard ratio [HR] = 1.28, 95% CI = 1.002-1.64, P = 0.049) but not mortality (HR = 1.62, CI = 0.71-3.68, P = 0.25), whereas preoperative BNP independently predicted HLOS (HR = 1.09, CI = 1.01-1.18, P = 0.03) and approached being an independent predictor of mortality (HR = 1.36, CI = 0.96-1.94, P = 0.08). When preoperative and peak postoperative BNP were separately adjusted for within the clinical multivariable models, each independently predicted HLOS (preoperative BNP HR = 1.13, CI = 1.05-1.21, P = 0.0007; peak postoperative BNP HR = 1.44, CI = 1.15-1.81, P = 0.001) and mortality (preoperative BNP HR = 1.50, CI = 1.09-2.07, P = 0.01; peak postoperative BNP HR = 2.29, CI = 1.11-4.73, P = 0.02).

Conclusions: Preoperative BNP may be better than peak postoperative BNP for predicting HLOS and longer term mortality after primary coronary artery bypass grafting surgery.

Citing Articles

The Value of Biomarkers in Major Cardiovascular Surgery Necessitating Cardiopulmonary Bypass.

Stef A, Bodolea C, Bocsan I, Cainap S, Achim A, Serban A Rev Cardiovasc Med. 2024; 25(10):355.

PMID: 39484111 PMC: 11522763. DOI: 10.31083/j.rcm2510355.

Effect of glutamate infusion on NT-proBNP after coronary artery bypass grafting in high-risk patients (GLUTAMICS II): A randomized controlled trial.

Holm J, Ferrari G, Holmgren A, Vanky F, Friberg O, Vidlund M PLoS Med. 2022; 19(5):e1003997.

PMID: 35533197 PMC: 9126383. DOI: 10.1371/journal.pmed.1003997.

Perioperative Biomarkers Predicting Postoperative Atrial Fibrillation Risk After Coronary Artery Bypass Grafting: A Narrative Review.

Khan M, Yamashita K, Sharma V, Ranjan R, Selzman C, Dosdall D J Cardiothorac Vasc Anesth. 2019; 34(7):1933-1941.

PMID: 31653497 PMC: 7078035. DOI: 10.1053/j.jvca.2019.09.022.

Platelet-leukocyte aggregate is associated with adverse events after surgical intervention for rheumatic heart disease.

Liu C, Yang Y, Du L, Chen S, Zhang J, Zhang C Sci Rep. 2019; 9(1):13069.

PMID: 31506454 PMC: 6737193. DOI: 10.1038/s41598-019-49253-3.

In-hospital mortality is associated with high NT-proBNP level.

Benmachiche M, Marques-Vidal P, Waeber G, Mean M PLoS One. 2018; 13(11):e0207118.

PMID: 30408101 PMC: 6224094. DOI: 10.1371/journal.pone.0207118.

References

Mega J, Morrow D, de Lemos J, Sabatine M, Murphy S, Rifai N . B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol. 2004; 44(2):335-9. DOI: 10.1016/j.jacc.2004.04.033. View

Hsieh F, Lavori P . Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials. 2001; 21(6):552-60. DOI: 10.1016/s0197-2456(00)00104-5. View

Hutfless R, Kazanegra R, Madani M, Bhalla M, Tulua-Tata A, Chen A . Utility of B-type natriuretic peptide in predicting postoperative complications and outcomes in patients undergoing heart surgery. J Am Coll Cardiol. 2004; 43(10):1873-9. DOI: 10.1016/j.jacc.2003.12.048. View

. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2 Suppl 1):S1-266. View

Daniels L, Maisel A . Natriuretic peptides. J Am Coll Cardiol. 2007; 50(25):2357-68. DOI: 10.1016/j.jacc.2007.09.021. View

Cuthbertson B, Amiri A, Croal B, Rajagopalan S, Brittenden J, Hillis G . Utility of B-type natriuretic peptide in predicting medium-term mortality in patients undergoing major non-cardiac surgery. Am J Cardiol. 2007; 100(8):1310-3. DOI: 10.1016/j.amjcard.2007.05.058. View

Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130(6):461-70. DOI: 10.7326/0003-4819-130-6-199903160-00002. View

Fox A, Collard C, Shernan S, Seidman C, Seidman J, Liu K . Natriuretic peptide system gene variants are associated with ventricular dysfunction after coronary artery bypass grafting. Anesthesiology. 2009; 110(4):738-47. PMC: 2735337. DOI: 10.1097/aln.0b013e31819c7496. View

de Lemos J, Morrow D, Bentley J, Omland T, Sabatine M, McCabe C . The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001; 345(14):1014-21. DOI: 10.1056/NEJMoa011053. View

10.

Fonarow G, Peacock W, Horwich T, Phillips C, Givertz M, Lopatin M . Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE. Am J Cardiol. 2008; 101(2):231-7. DOI: 10.1016/j.amjcard.2007.07.066. View

11.

Bassan R, Tura B, Maisel A . B-type natriuretic peptide: a strong predictor of early and late mortality in patients with acute chest pain without ST-segment elevation in the emergency department. Coron Artery Dis. 2009; 20(2):143-9. DOI: 10.1097/MCA.0b013e3283292ac6. View

12.

Maisel A, Hollander J, Guss D, McCullough P, Nowak R, Green G . Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol. 2004; 44(6):1328-33. DOI: 10.1016/j.jacc.2004.06.015. View

13.

Fox A, Shernan S, Collard C, Liu K, Aranki S, DeSantis S . Preoperative B-type natriuretic peptide is as independent predictor of ventricular dysfunction and mortality after primary coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2008; 136(2):452-61. PMC: 2739747. DOI: 10.1016/j.jtcvs.2007.12.036. View

14.

Alibay Y, Beauchet A, El Mahmoud R, Schmitt C, Brun-Ney D, Benoit M . Plasma N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in assessment of acute dyspnea. Biomed Pharmacother. 2005; 59(1-2):20-4. DOI: 10.1016/j.biopha.2004.06.002. View

15.

Bail D, Kofler M, Ziemer G . Brain natriuretic peptide (BNP) in patients undergoing coronary artery bypass grafting. Thorac Cardiovasc Surg. 2004; 52(3):135-40. DOI: 10.1055/s-2004-817875. View

16.

Doust J, Pietrzak E, Dobson A, Glasziou P . How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ. 2005; 330(7492):625. PMC: 554905. DOI: 10.1136/bmj.330.7492.625. View

17.

Wang T, Larson M, Levy D, Benjamin E, Leip E, Omland T . Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004; 350(7):655-63. DOI: 10.1056/NEJMoa031994. View

18.

Schnabel R, Lubos E, Rupprecht H, Espinola-Klein C, Bickel C, Lackner K . B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the AtheroGene study. J Am Coll Cardiol. 2006; 47(3):552-8. DOI: 10.1016/j.jacc.2005.09.039. View

19.

Das S, Abdullah S, Leonard D, Drazner M, Khera A, McGuire D . Association between renal function and circulating levels of natriuretic peptides (from the Dallas Heart Study). Am J Cardiol. 2008; 102(10):1394-8. DOI: 10.1016/j.amjcard.2008.07.018. View

20.

Wahl H, Graf S, Renz H, Fassbinder W . Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis. Clin Chem. 2004; 50(6):1071-4. DOI: 10.1373/clinchem.2003.030692. View